ARA-290 in Nonclinical Peptide Research
ARA-290, also known as cibinetide, is an 11-amino-acid peptide designed from structural features of erythropoietin (EPO). Its research context includes EPO-related signaling, the proposed innate repair receptor, and experimental measurements of nerve-associated inflammation. These subjects require a clear distinction between molecular hypotheses, animal experiments, and studies involving human participants.
This article provides a framework for evaluating that literature and documenting material used in nonclinical laboratory work. The ARA-290 catalog entry is separate from the published studies: findings involving a study preparation do not establish the identity, activity, or suitability of an Alpha Carbon Labs lot.
Chemical Identity and Design Context
ARA-290 is a synthetic peptide based on the tertiary structure of EPO, rather than simply an 11-residue segment excised from the EPO amino-acid sequence. EPO and ARA-290 are distinct molecules; their names and structural relationship should not be treated as evidence of equivalent receptor interactions or biological activity.
For laboratory records, the common name and peptide length are not sufficient to define a material. Record the documented sequence, terminal modifications, counterion, formulation, lot identifier, and available analytical results. The supplied article does not provide a verified sequence specification, molecular formula, molecular mass, or numerical acceptance criteria, so none are assigned here.
The Innate Repair Receptor as a Research Hypothesis
The reviews by Brines and Cerami (2012) and Chen and colleagues (2018) discuss EPO-related signaling and the innate repair receptor across experimental literature, rather than reporting a single ARA-290 study population [1, 10]. In this framework, the proposed receptor complex involves the EPO receptor and the common beta receptor subunit, CD131. This is a mechanistic framework to evaluate, not evidence that every cell type expresses a functional complex or responds to a particular peptide preparation.
A receptor-associated explanation requires more than a downstream change in a cytokine measurement. In a nonclinical experiment, receptor-expression measurements, appropriate negative controls, and a validated perturbation of the proposed pathway can help distinguish receptor involvement from nonspecific effects. These are experimental-design considerations, not findings established for Alpha Carbon Labs material.
Likewise, a designation such as “nonerythropoietic” in the literature does not establish general safety, exclusive receptor binding, or the absence of other biological effects. Such characterizations must be interpreted within the assays and conditions in which they were investigated.
Separating the Evidence by Study Type
The supplied references include animal research, human studies, and reviews. They should not be combined into a single claim of nerve repair. The following overview identifies selected study contexts without presenting their titles or endpoints as evidence of product performance.
| Reference | Model or population | Interpretive boundary |
|---|---|---|
| Swartjes et al. (2011) [4] | Animal research involving an experimental neuropathic pain model. | Behavioral measurements in an animal model are not human symptom reports or direct evidence of nerve regeneration. |
| Dahan et al. (2013) [2] | Human participants with sarcoidosis-associated small nerve fiber neuropathy. | Clinical symptom measurements in this population do not establish activity in a laboratory assay or performance of a commercially supplied material. |
| Brines et al. (2015) [5] | Human participants with type 2 diabetes; the study concerns metabolic and neuropathic endpoints. | These endpoints cannot be generalized to other populations, experimental systems, or peptide lots. |
| Culver et al. (2017) [6] | Human participants with sarcoidosis-associated small nerve fiber neuropathy; the study concerns corneal nerve fiber abundance. | A corneal nerve measurement is anatomically specific and does not establish whole-body nerve regeneration or durable functional recovery. |
No specific in-vitro or in-silico result is established by this overview. A cellular mechanism should not be inferred solely from an animal behavioral endpoint or a human clinical measurement. Before using any cited paper to justify a laboratory method, consult its full methods, controls, statistical analysis, and limitations.
Interpreting Nerve and Inflammatory Endpoints
Inflammatory markers, cellular morphology, nerve-fiber measurements, and behavioral responses address different experimental questions. A change in one does not establish a change in the others. In particular, cytokine measurements alone do not demonstrate axonal regeneration, and a structural measurement alone does not establish restored function.
For nonclinical assay planning, define the endpoint before collecting data and document:
- The experimental system, including species or cell source and relevant culture or model conditions.
- The exact material lot, preparation records, vehicle controls, and exposure conditions.
- The assay method, calibration, detection limits, and normalization procedure.
- Biological and technical replication, prespecified exclusions, and statistical comparisons.
- Potential confounders, including loss of cell viability, assay interference, and variation in sample composition.
These records support reproducibility and interpretation. They do not convert a laboratory observation into a clinical conclusion.
Analytical Documentation and Laboratory Handling
Identity, chromatographic purity, and peptide content are separate analytical questions. Mass spectrometry can support identity assessment, while a chromatographic method can characterize components resolved under its particular conditions. Neither a matching mass nor a single purity percentage establishes complete sequence verification, sterility, or absence of all contaminants.
Review any lot-specific certificate of analysis for the method used, reported result, acceptance criterion, and scope of testing. Endotoxin, residual solvent, or elemental-impurity status should be treated as unestablished unless the relevant testing is documented. A result below a method's detection or reporting limit is not proof of total absence.
The site's peptide synthesis and quality control information can provide documentation context, but general process descriptions are not substitutes for lot-specific evidence. The supplied material does not substantiate universal independent testing or numerical purity specifications, so no such claims are made here.
Use the applicable safety data sheet, documented storage requirements, and institutional chemical-hygiene procedures. Select protective equipment and containment through the laboratory's risk assessment, minimize unnecessary exposure, and dispose of material under local procedures. No specific stability period, storage temperature, or hazard classification is established by the supplied article. Missing hazard information must not be interpreted as evidence of harmlessness.
Questions for Critical Literature Review
- Does a shared peptide name establish comparability between studies?
No. Compare the documented chemical identity, formulation, analytical characterization, experimental system, and endpoint. A publication does not characterize a supplier's separate material.
- Does a receptor hypothesis establish a universal response?
No. Receptor expression, pathway involvement, and assay specificity require evaluation in the actual experimental system.
- Can published observations define a general response timeline?
No. Sampling schedules and observations belong to the particular study design. They do not establish a general sequence of inflammatory changes followed by nerve regeneration.
- Do the cited papers validate combinations with other catalog peptides?
No evidence supplied with this article establishes such combinations. They are not recommended or inferred here.
References
- Brines, M., & Cerami, A. (2012). Erythropoietin-mediated tissue protection: reducing collateral damage from the inflammatory response. Journal of Internal Medicine. — https://doi.org/10.1111/j.1365-2796.2012.02542.x
- Dahan, A., et al. (2013). ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber neuropathy. Pain. — https://doi.org/10.1016/j.pain.2013.06.002
- Hebert, H. L., et al. (2014). Disease-modifying therapy for small fiber neuropathy: a randomized, double-blind, placebo-controlled trial of ARA 290. Molecular Medicine.
- Swartjes, M., et al. (2011). ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain. Anesthesiology. — https://doi.org/10.1097/aln.0b013e31822fcefd
- Brines, M., et al. (2015). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic pain in patients with type 2 diabetes. Molecular Medicine. — https://doi.org/10.2119/molmed.2014.00215
- Culver, D. A., et al. (2017). Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber neuropathy. Investigative Ophthalmology & Visual Science. — https://doi.org/10.1167/iovs.16-21291
- Collino, M., et al. (2015). ARA290 attenuates lipopolysaccharide-induced acute renal failure. European Journal of Pharmacology. — https://doi.org/10.1016/j.ejphar.2015.04.032
- Niesters, M., et al. (2014). ARA 290 for the treatment of painful small fiber neuropathy in sarcoidosis. Expert Opinion on Orphan Drugs. — https://doi.org/10.1517/13543784.2014.892072
- Peng, B., et al. (2020). Erythropoietin-derived peptide ARA290 attenuates mechanical allodynia and neuroinflammation. Neuroscience Letters. — https://doi.org/10.1016/j.neulet.2020.135246
- Chen, H., et al. (2018). The innate repair receptor: a new target for tissue protection and regeneration in neurodegenerative diseases. Frontiers in Cellular Neuroscience. — https://doi.org/10.3389/fncel.2018.00101